サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1472399

中核的臨床分子診断市場：製品タイプ別、技術別、用途別：世界の機会分析と産業予測、2023年～2032年

Core Clinical Molecular Diagnostics Market By Product type, By Technique (PCR, Nucleic Acid Sequencing, Fluorescence In Situ Hybridization, Others), By Application : Global Opportunity Analysis and Industry Forecast, 2023-2032

出版日
ページ情報
英文 257 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
中核的臨床分子診断市場：製品タイプ別、技術別、用途別：世界の機会分析と産業予測、2023年～2032年
出版日: 2024年03月01日
発行: Allied Market Research
ページ情報: 英文 257 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

中核的臨床分子診断市場は、2022年に48億米ドルと評価され、2023年から2032年までのCAGRは9.50％を示し、2032年には119億米ドルに達すると推定されます。

中核的な臨床分子診断とは、医療検査室で実施される必須の技術や手順を指します。分子レベルでの遺伝物質（DNA、RNA）およびタンパク質の分析に重点を置き、疾患の診断や治療方針の決定に役立てる。これらの診断手法には、ポリメラーゼ連鎖反応（PCR）、DNAシークエンシング、次世代シークエンシング（NGS）、蛍光その場ハイブリダイゼーション（FISH）、免疫組織化学（IHC）など様々な手法が含まれます。中核的な臨床分子診断学は、遺伝子変異、感染因子、疾患に関連するバイオマーカーを同定することで、患者に合わせた治療を可能にし、臨床転帰を改善する個別化医療において重要な役割を果たしています。

Core Clinical Molecular Diagnostics Market-IMG1

疾患の蔓延と人口の高齢化は、臨床分子診断薬に対する需要拡大の大きな原動力となっています。人口の高齢化に伴い、がん、心血管疾患、神経変性疾患などの慢性疾患や加齢に関連する疾患の罹患率が著しく上昇します。また、高齢化により免疫力が低下するため、感染症にかかりやすくなります。米国国勢調査局から入手したデータによると、2021年、米国の高齢者人口は総人口の16.5％、5,400万人を占める。さらに、この数は2050年までに8,570万人に増加すると予測されています。また、米国国立がん研究所によると、診断年齢の中央値は乳がんで61歳、大腸がんで68歳、肺がんで70歳、前立腺がんで66歳です。

したがって、臨床分子診断学は、特定の疾患に関連する遺伝子変異、感染因子、バイオマーカーを同定することにより、これらの疾患を正確に診断する上で重要な役割を果たします。正確でタイムリーな診断情報を提供する能力により、ヘルスケアプロバイダーは個別化された治療戦略を実施することができ、患者の転帰を改善し、高齢化社会におけるより効果的な疾病管理に貢献することができます。このように、中核的な臨床分子診断薬に対する需要は、世界の高齢化社会のヘルスケアニーズに対応するため、今後も増加し続けると予想されます。

加えて、ヘルスケアへの支出が増加していることも、中核的臨床分子診断薬市場の成長を後押しする重要な要因となっています。ヘルスケアへの支出が世界的に増加するにつれ、患者のケアと転帰を向上させるための診断能力の向上が重視されるようになっています。臨床コア分子診断の能力は、精密で個別化された診断情報を提供するものであり、精密医療への高まりつつある動向とよく合致しています。ヘルスケアにより多くの資源が割り当てられる中、PCR、DNAシークエンシング、NGSのような高度な診断技術に投資する能力と意欲が高まり、市場成長を牽引しています。さらに、ヘルスケアシステムが資源利用の最適化と費用対効果の改善に努める中、中核的臨床分子診断薬が提供する効率性と精度がますます魅力的になり、市場拡大をさらに後押ししています。

中核的臨床分子診断市場は、製品タイプ、技術、用途、地域によって区分されます。製品タイプ別では、市場は装置、試薬、ソフトウェア＆サービスに区分されます。技術別では、市場はPCR、核酸配列決定、蛍光in situハイブリダイゼーション（FISH）、その他に区分されます。アプリケーション別では、市場は感染症、遺伝子疾患、がんスクリーニング、その他に区分されます。地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、その他欧州地域）、アジア太平洋地域（中国、日本、インド、オーストラリア、韓国、その他アジア太平洋地域）、LA（ブラジル、コロンビア、アルゼンチン、その他LA地域）、MEA（GCC、北アフリカ、その他MEA地域）で分析されます。

利害関係者にとっての主なメリット

  • 当レポートは、2022年から2032年までの中核的臨床分子診断市場分析の市場セグメント、現在の動向、推定・動向、力学の定量分析を提供し、中核的臨床分子診断市場の有力な市場機会を特定します。
  • 市場促進要因、市場抑制要因、市場機会に関連する情報とともに市場調査を提供します。
  • ポーターのファイブフォース分析では、利害関係者が利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるよう、バイヤーとサプライヤーの潜在力を明らかにします。
  • 中核となる臨床分子診断市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
  • 各地域の主要国は、世界市場への収益貢献度に応じてマッピングされています。
  • 市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
  • 本レポートには、地域別および世界の中核的臨床分子診断薬市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析が含まれています。

本レポートはカスタマイズが可能です。

  • 規制ガイドライン
  • 顧客の関心に応じた企業プロファイルの追加
  • 企業プロファイルの拡張リスト
  • 過去の市場データ

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
    • 影響要因
    • 主な投資機会
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会

第4章 臨床用分子診断薬の中核市場：製品タイプ別

  • 概要
  • 検査機器
  • 試薬
  • ソフトウェアとサービス

第5章 中核的臨床分子診断市場：技術別

  • 概要
  • PCR法
  • 核酸配列決定
  • 蛍光in situハイブリダイゼーション（FISH）
  • その他

第6章 中核的臨床分子診断市場：用途別

  • 概要
  • 感染症
  • 遺伝子疾患
  • がんスクリーニング
  • その他

第7章 中核的臨床分子診断市場：地域別

  • 概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • その他
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • その他
  • ラテンアメリカ
    • ブラジル
    • コロンビア
    • アルゼンチン
    • その他のラテンアメリカ
  • 中東・アフリカ
    • Gcc
    • 南アフリカ
    • 北アフリカ
    • その他

第8章 競争情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング、2022年

第9章 企業プロファイル

  • F. Hoffmann La Roche
  • Novartis AG
  • Abbott Laboratories
  • Becton Dickinson & Company
  • Siemens Healthineers AG
  • Agilent Technologies, Inc.
  • Hologic, Inc.
  • BioMerieux SA
  • Qiagen NV.
  • cepheid ab
図表

LIST OF TABLES

  • TABLE 01. GLOBAL CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 02. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR SOFTWARE AND SERVICES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
  • TABLE 06. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR PCR, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR NUCLEIC ACID SEQUENCING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 11. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR GENETIC DISORDER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR CANCER SCREENING, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 20. U.S. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 21. U.S. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
  • TABLE 22. U.S. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 23. CANADA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 24. CANADA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
  • TABLE 25. CANADA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 26. MEXICO CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 27. MEXICO CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
  • TABLE 28. MEXICO CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
  • TABLE 31. EUROPE CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 32. EUROPE CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 33. GERMANY CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 34. GERMANY CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
  • TABLE 35. GERMANY CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 36. FRANCE CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 37. FRANCE CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
  • TABLE 38. FRANCE CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 39. UK CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 40. UK CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
  • TABLE 41. UK CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 42. ITALY CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 43. ITALY CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
  • TABLE 44. ITALY CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 45. SPAIN CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 46. SPAIN CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
  • TABLE 47. SPAIN CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 48. REST OF EUROPE CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 49. REST OF EUROPE CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
  • TABLE 50. REST OF EUROPE CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 52. ASIA-PACIFIC CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
  • TABLE 53. ASIA-PACIFIC CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 54. ASIA-PACIFIC CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 55. JAPAN CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 56. JAPAN CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
  • TABLE 57. JAPAN CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 58. CHINA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 59. CHINA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
  • TABLE 60. CHINA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 61. INDIA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 62. INDIA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
  • TABLE 63. INDIA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 64. AUSTRALIA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 65. AUSTRALIA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
  • TABLE 66. AUSTRALIA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH KOREA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 68. SOUTH KOREA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
  • TABLE 69. SOUTH KOREA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 71. REST OF ASIA-PACIFIC CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
  • TABLE 72. REST OF ASIA-PACIFIC CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 73. LATIN AMERICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 74. LATIN AMERICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
  • TABLE 75. LATIN AMERICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 76. LATIN AMERICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 77. BRAZIL CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 78. BRAZIL CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
  • TABLE 79. BRAZIL CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 80. COLOMBIA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 81. COLOMBIA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
  • TABLE 82. COLOMBIA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 83. ARGENTINA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 84. ARGENTINA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
  • TABLE 85. ARGENTINA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 86. REST OF LA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 87. REST OF LA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
  • TABLE 88. REST OF LA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 89. MIDDLE EAST AND AFRICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 90. MIDDLE EAST AND AFRICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
  • TABLE 91. MIDDLE EAST AND AFRICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 92. MIDDLE EAST AND AFRICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 93. GCC CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 94. GCC CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
  • TABLE 95. GCC CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 96. SOUTH AFRICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 97. SOUTH AFRICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
  • TABLE 98. SOUTH AFRICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 99. NORTH AFRICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 100. NORTH AFRICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
  • TABLE 101. NORTH AFRICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 102. REST OF MEA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 103. REST OF MEA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022-2032 ($MILLION)
  • TABLE 104. REST OF MEA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 105. F. HOFFMANN LA ROCHE: KEY EXECUTIVES
  • TABLE 106. F. HOFFMANN LA ROCHE: COMPANY SNAPSHOT
  • TABLE 107. F. HOFFMANN LA ROCHE: PRODUCT SEGMENTS
  • TABLE 108. F. HOFFMANN LA ROCHE: SERVICE SEGMENTS
  • TABLE 109. F. HOFFMANN LA ROCHE: PRODUCT PORTFOLIO
  • TABLE 110. F. HOFFMANN LA ROCHE: KEY STRATERGIES
  • TABLE 111. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 112. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 113. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 114. NOVARTIS AG: SERVICE SEGMENTS
  • TABLE 115. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 116. NOVARTIS AG: KEY STRATERGIES
  • TABLE 117. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 118. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 119. ABBOTT LABORATORIES: PRODUCT SEGMENTS
  • TABLE 120. ABBOTT LABORATORIES: SERVICE SEGMENTS
  • TABLE 121. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 122. ABBOTT LABORATORIES: KEY STRATERGIES
  • TABLE 123. BECTON DICKINSON & COMPANY: KEY EXECUTIVES
  • TABLE 124. BECTON DICKINSON & COMPANY: COMPANY SNAPSHOT
  • TABLE 125. BECTON DICKINSON & COMPANY: PRODUCT SEGMENTS
  • TABLE 126. BECTON DICKINSON & COMPANY: SERVICE SEGMENTS
  • TABLE 127. BECTON DICKINSON & COMPANY: PRODUCT PORTFOLIO
  • TABLE 128. BECTON DICKINSON & COMPANY: KEY STRATERGIES
  • TABLE 129. SIEMENS HEALTHINEERS AG: KEY EXECUTIVES
  • TABLE 130. SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT
  • TABLE 131. SIEMENS HEALTHINEERS AG: PRODUCT SEGMENTS
  • TABLE 132. SIEMENS HEALTHINEERS AG: SERVICE SEGMENTS
  • TABLE 133. SIEMENS HEALTHINEERS AG: PRODUCT PORTFOLIO
  • TABLE 134. SIEMENS HEALTHINEERS AG: KEY STRATERGIES
  • TABLE 135. AGILENT TECHNOLOGIES, INC.: KEY EXECUTIVES
  • TABLE 136. AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
  • TABLE 137. AGILENT TECHNOLOGIES, INC.: PRODUCT SEGMENTS
  • TABLE 138. AGILENT TECHNOLOGIES, INC.: SERVICE SEGMENTS
  • TABLE 139. AGILENT TECHNOLOGIES, INC.: PRODUCT PORTFOLIO
  • TABLE 140. AGILENT TECHNOLOGIES, INC.: KEY STRATERGIES
  • TABLE 141. HOLOGIC, INC.: KEY EXECUTIVES
  • TABLE 142. HOLOGIC, INC.: COMPANY SNAPSHOT
  • TABLE 143. HOLOGIC, INC.: PRODUCT SEGMENTS
  • TABLE 144. HOLOGIC, INC.: SERVICE SEGMENTS
  • TABLE 145. HOLOGIC, INC.: PRODUCT PORTFOLIO
  • TABLE 146. HOLOGIC, INC.: KEY STRATERGIES
  • TABLE 147. BIOMERIEUX SA: KEY EXECUTIVES
  • TABLE 148. BIOMERIEUX SA: COMPANY SNAPSHOT
  • TABLE 149. BIOMERIEUX SA: PRODUCT SEGMENTS
  • TABLE 150. BIOMERIEUX SA: SERVICE SEGMENTS
  • TABLE 151. BIOMERIEUX SA: PRODUCT PORTFOLIO
  • TABLE 152. BIOMERIEUX SA: KEY STRATERGIES
  • TABLE 153. QIAGEN NV.: KEY EXECUTIVES
  • TABLE 154. QIAGEN NV.: COMPANY SNAPSHOT
  • TABLE 155. QIAGEN NV.: PRODUCT SEGMENTS
  • TABLE 156. QIAGEN NV.: SERVICE SEGMENTS
  • TABLE 157. QIAGEN NV.: PRODUCT PORTFOLIO
  • TABLE 158. QIAGEN NV.: KEY STRATERGIES
  • TABLE 159. CEPHEID AB: KEY EXECUTIVES
  • TABLE 160. CEPHEID AB: COMPANY SNAPSHOT
  • TABLE 161. CEPHEID AB: PRODUCT SEGMENTS
  • TABLE 162. CEPHEID AB: SERVICE SEGMENTS
  • TABLE 163. CEPHEID AB: PRODUCT PORTFOLIO
  • TABLE 164. CEPHEID AB: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET
  • FIGURE 04. TOP INVESTMENT POCKETS IN CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET (2023-2032)
  • FIGURE 05. BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. BARGAINING POWER OF BUYERS
  • FIGURE 07. THREAT OF SUBSTITUTION
  • FIGURE 08. THREAT OF SUBSTITUTION
  • FIGURE 09. COMPETITIVE RIVALRY
  • FIGURE 10. GLOBAL CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR REAGENTS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR SOFTWARE AND SERVICES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE, 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR PCR, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR NUCLEIC ACID SEQUENCING, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION, 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR GENETIC DISORDER, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR CANCER SCREENING, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 24. COMPARATIVE SHARE ANALYSIS OF CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 25. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 26. U.S. CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. CANADA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. MEXICO CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. GERMANY CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. FRANCE CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. UK CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. ITALY CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. SPAIN CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. REST OF EUROPE CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. JAPAN CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. CHINA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. INDIA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. AUSTRALIA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. SOUTH KOREA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. REST OF ASIA-PACIFIC CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. BRAZIL CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. COLOMBIA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. ARGENTINA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 44. REST OF LA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 45. GCC CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 46. SOUTH AFRICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 47. NORTH AFRICA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 48. REST OF MEA CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 49. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 50. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 51. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 52. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 53. COMPETITIVE DASHBOARD
  • FIGURE 54. COMPETITIVE HEATMAP: CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET
  • FIGURE 55. TOP PLAYER POSITIONING, 2022
目次
Product Code: A323203

The core clinical molecular diagnostics market was valued at $4.8 billion in 2022 and is estimated to reach $11.9 billion by 2032, exhibiting a CAGR of 9.50% from 2023 to 2032. Core clinical molecular diagnostics refer to essential techniques and procedures conducted in medical laboratories. They focus on analyzing genetic material (DNA, RNA) and proteins at the molecular level to diagnose diseases and guide treatment decisions. These diagnostics encompass various methodologies such as Polymerase Chain Reaction (PCR), DNA sequencing, Next-Generation Sequencing (NGS), Fluorescence In Situ Hybridization (FISH), and immunohistochemistry (IHC). Core clinical molecular diagnostics play a crucial role in personalized medicine by identifying genetic variations, infectious agents, and biomarkers associated with diseases, enabling tailored patient care and improving clinical outcomes.

Core Clinical Molecular Diagnostics Market - IMG1

The increasing prevalence of diseases and the aging population are major driving forces behind the growing demand for core clinical molecular diagnostics. As populations age, the incidence of chronic and age-related diseases such as cancer, cardiovascular diseases, and neurodegenerative disorders rises significantly. Additionally, the aging demographic is more susceptible to infectious diseases due to weakened immune systems. According to data obtained from the U.S. Census Bureau, in 2021, elderly population in the U.S. accounted for 16.5% of the total population, which is 54 million. Moreover, this number is anticipated to increase to 85.7 million by 2050. In addition, according to the National Cancer Institute, the median age for diagnosis is 61 years for breast cancer, 68 years for colorectal cancer, 70 years for lung cancer, and 66 years for prostate cancer.

Thus, clinical molecular diagnostics play a critical role in accurately diagnosing these conditions by identifying genetic variations, infectious agents, and biomarkers associated with specific diseases. Their ability to provide precise and timely diagnostic information enables healthcare providers to implement personalized treatment strategies, improving patient outcomes and contributing to more effective disease management in an aging population. As such, the demand for core clinical molecular diagnostics is expected to continue increasing to meet the healthcare needs of aging populations worldwide.

In addition, the rising expenditure in healthcare is indeed a significant driver propelling the growth of the core clinical molecular diagnostics market. As healthcare spending increases globally, there's a greater emphasis on improving diagnostic capabilities to enhance patient care and outcomes. The ability of clinical core molecular diagnostics offers precise and personalized diagnostic information, which aligns well with the growing trend towards precision medicine. With more resources being allocated to healthcare, there's an increased ability and willingness to invest in advanced diagnostic technologies such as PCR, DNA sequencing, and NGS, driving market growth. Additionally, as healthcare systems strive to optimize resource utilization and improve cost-effectiveness, the efficiency and accuracy offered by core clinical molecular diagnostics become increasingly attractive, further fueling market expansion.

The core clinical molecular diagnostics market is segmented on the basis of product type, technique, application, and region. On the basis of product type, the market is segmented into Instruments, reagents and software & services. On the basis of technique, the market is segmented into PCR, nucleic acid sequencing, fluorescence in situ hybridization (FISH), and others. On the basis of application, the market is segmented into infectious diseases, genetic disorders, cancer screening, and others. Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LA (Brazil, Colombia, Argentina, and rest of LA) and MEA (GCC, South Africa, North Africa and rest of MEA).

The major key players that operate in the core clinical molecular diagnostics market are F. Hoffmann-La Roche Ltd., Novartis, Abbott Laboratories, Becton, Dickinson and Company, Siemens Healthineers, Agilent Technologies, Hologic, Inc. Bio-Rad Laboratories, Inc., Qiagen and bioMerieux. The key players have adopted product launch, product development and product approval as the key strategy to expand their product portfolio.

Key Benefits for Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the core clinical molecular diagnostics market analysis from 2022 to 2032 to identify the prevailing core clinical molecular diagnostics market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the core clinical molecular diagnostics market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global core clinical molecular diagnostics market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Expanded list for Company Profiles
  • Historic market data

Key Market Segments

By Product type

  • Instruments
  • Reagents
  • Software and Services

By Technique

  • PCR
  • Nucleic Acid Sequencing
  • Fluorescence In Situ Hybridization (FISH)
  • Others

By Application

  • Infectious Disease
  • Genetic disorder
  • Cancer Screening
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Colombia
    • Argentina
    • Rest Of La
  • Middle East and Africa
    • Gcc
    • South Africa
    • North Africa
    • Rest Of Mea

Key Market Players:

    • F. Hoffmann La Roche
    • Novartis AG
    • Abbott Laboratories
    • Becton Dickinson & Company
    • Siemens Healthineers AG
    • Agilent Technologies, Inc.
    • Hologic, Inc.
    • BioMerieux SA
    • Qiagen NV.
    • cepheid ab

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
  • 3.4. Market dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Instruments
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Reagents
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Software and Services
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. PCR
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Nucleic Acid Sequencing
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Fluorescence In Situ Hybridization (FISH)
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country
  • 5.5. Others
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by region
    • 5.5.3. Market share analysis by country

CHAPTER 6: CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Infectious Disease
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Genetic disorder
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Cancer Screening
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country
  • 6.5. Others
    • 6.5.1. Key market trends, growth factors and opportunities
    • 6.5.2. Market size and forecast, by region
    • 6.5.3. Market share analysis by country

CHAPTER 7: CORE CLINICAL MOLECULAR DIAGNOSTICS MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by Product type
    • 7.2.3. Market size and forecast, by Technique
    • 7.2.4. Market size and forecast, by Application
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Market size and forecast, by Product type
      • 7.2.5.1.2. Market size and forecast, by Technique
      • 7.2.5.1.3. Market size and forecast, by Application
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Market size and forecast, by Product type
      • 7.2.5.2.2. Market size and forecast, by Technique
      • 7.2.5.2.3. Market size and forecast, by Application
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Market size and forecast, by Product type
      • 7.2.5.3.2. Market size and forecast, by Technique
      • 7.2.5.3.3. Market size and forecast, by Application
  • 7.3. Europe
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by Product type
    • 7.3.3. Market size and forecast, by Technique
    • 7.3.4. Market size and forecast, by Application
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Market size and forecast, by Product type
      • 7.3.5.1.2. Market size and forecast, by Technique
      • 7.3.5.1.3. Market size and forecast, by Application
      • 7.3.5.2. France
      • 7.3.5.2.1. Market size and forecast, by Product type
      • 7.3.5.2.2. Market size and forecast, by Technique
      • 7.3.5.2.3. Market size and forecast, by Application
      • 7.3.5.3. UK
      • 7.3.5.3.1. Market size and forecast, by Product type
      • 7.3.5.3.2. Market size and forecast, by Technique
      • 7.3.5.3.3. Market size and forecast, by Application
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Market size and forecast, by Product type
      • 7.3.5.4.2. Market size and forecast, by Technique
      • 7.3.5.4.3. Market size and forecast, by Application
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Market size and forecast, by Product type
      • 7.3.5.5.2. Market size and forecast, by Technique
      • 7.3.5.5.3. Market size and forecast, by Application
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Market size and forecast, by Product type
      • 7.3.5.6.2. Market size and forecast, by Technique
      • 7.3.5.6.3. Market size and forecast, by Application
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by Product type
    • 7.4.3. Market size and forecast, by Technique
    • 7.4.4. Market size and forecast, by Application
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Market size and forecast, by Product type
      • 7.4.5.1.2. Market size and forecast, by Technique
      • 7.4.5.1.3. Market size and forecast, by Application
      • 7.4.5.2. China
      • 7.4.5.2.1. Market size and forecast, by Product type
      • 7.4.5.2.2. Market size and forecast, by Technique
      • 7.4.5.2.3. Market size and forecast, by Application
      • 7.4.5.3. India
      • 7.4.5.3.1. Market size and forecast, by Product type
      • 7.4.5.3.2. Market size and forecast, by Technique
      • 7.4.5.3.3. Market size and forecast, by Application
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Market size and forecast, by Product type
      • 7.4.5.4.2. Market size and forecast, by Technique
      • 7.4.5.4.3. Market size and forecast, by Application
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Market size and forecast, by Product type
      • 7.4.5.5.2. Market size and forecast, by Technique
      • 7.4.5.5.3. Market size and forecast, by Application
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Market size and forecast, by Product type
      • 7.4.5.6.2. Market size and forecast, by Technique
      • 7.4.5.6.3. Market size and forecast, by Application
  • 7.5. Latin America
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast, by Product type
    • 7.5.3. Market size and forecast, by Technique
    • 7.5.4. Market size and forecast, by Application
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Market size and forecast, by Product type
      • 7.5.5.1.2. Market size and forecast, by Technique
      • 7.5.5.1.3. Market size and forecast, by Application
      • 7.5.5.2. Colombia
      • 7.5.5.2.1. Market size and forecast, by Product type
      • 7.5.5.2.2. Market size and forecast, by Technique
      • 7.5.5.2.3. Market size and forecast, by Application
      • 7.5.5.3. Argentina
      • 7.5.5.3.1. Market size and forecast, by Product type
      • 7.5.5.3.2. Market size and forecast, by Technique
      • 7.5.5.3.3. Market size and forecast, by Application
      • 7.5.5.4. Rest Of La
      • 7.5.5.4.1. Market size and forecast, by Product type
      • 7.5.5.4.2. Market size and forecast, by Technique
      • 7.5.5.4.3. Market size and forecast, by Application
  • 7.6. Middle East and Africa
    • 7.6.1. Key market trends, growth factors and opportunities
    • 7.6.2. Market size and forecast, by Product type
    • 7.6.3. Market size and forecast, by Technique
    • 7.6.4. Market size and forecast, by Application
    • 7.6.5. Market size and forecast, by country
      • 7.6.5.1. Gcc
      • 7.6.5.1.1. Market size and forecast, by Product type
      • 7.6.5.1.2. Market size and forecast, by Technique
      • 7.6.5.1.3. Market size and forecast, by Application
      • 7.6.5.2. South Africa
      • 7.6.5.2.1. Market size and forecast, by Product type
      • 7.6.5.2.2. Market size and forecast, by Technique
      • 7.6.5.2.3. Market size and forecast, by Application
      • 7.6.5.3. North Africa
      • 7.6.5.3.1. Market size and forecast, by Product type
      • 7.6.5.3.2. Market size and forecast, by Technique
      • 7.6.5.3.3. Market size and forecast, by Application
      • 7.6.5.4. Rest Of Mea
      • 7.6.5.4.1. Market size and forecast, by Product type
      • 7.6.5.4.2. Market size and forecast, by Technique
      • 7.6.5.4.3. Market size and forecast, by Application

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product mapping of top 10 player
  • 8.4. Competitive dashboard
  • 8.5. Competitive heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. F. Hoffmann La Roche
    • 9.1.1. Company overview
    • 9.1.2. Key executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. Novartis AG
    • 9.2.1. Company overview
    • 9.2.2. Key executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. Abbott Laboratories
    • 9.3.1. Company overview
    • 9.3.2. Key executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. Becton Dickinson & Company
    • 9.4.1. Company overview
    • 9.4.2. Key executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
    • 9.4.7. Key strategic moves and developments
  • 9.5. Siemens Healthineers AG
    • 9.5.1. Company overview
    • 9.5.2. Key executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
    • 9.5.7. Key strategic moves and developments
  • 9.6. Agilent Technologies, Inc.
    • 9.6.1. Company overview
    • 9.6.2. Key executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
    • 9.6.7. Key strategic moves and developments
  • 9.7. Hologic, Inc.
    • 9.7.1. Company overview
    • 9.7.2. Key executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
    • 9.7.7. Key strategic moves and developments
  • 9.8. BioMerieux SA
    • 9.8.1. Company overview
    • 9.8.2. Key executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
    • 9.8.7. Key strategic moves and developments
  • 9.9. Qiagen NV.
    • 9.9.1. Company overview
    • 9.9.2. Key executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
    • 9.9.7. Key strategic moves and developments
  • 9.10. cepheid ab
    • 9.10.1. Company overview
    • 9.10.2. Key executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance
    • 9.10.7. Key strategic moves and developments